Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.328 USD | -1.09% | +0.77% | -93.74% |
Financials (USD)
Sales 2024 * | 1.58M | Sales 2025 * | 807K | Capitalization | 20M |
---|---|---|---|---|---|
Net income 2024 * | -87M | Net income 2025 * | -86M | EV / Sales 2024 * | 12.7 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 24.8 x |
P/E ratio 2024 * |
-0.26
x | P/E ratio 2025 * |
-0.31
x | Employees | 109 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 78.37% |
Latest transcript on Lyra Therapeutics, Inc.
1 day | -1.09% | ||
1 week | +0.77% | ||
1 month | -93.64% | ||
3 months | -93.76% | ||
6 months | -90.09% | ||
Current year | -93.74% |
Managers | Title | Age | Since |
---|---|---|---|
Maria Palasis
CEO | Chief Executive Officer | 59 | 14-12-31 |
Jason Cavalier
DFI | Director of Finance/CFO | 51 | 21-09-12 |
Richard Nieman
CTO | Chief Tech/Sci/R&D Officer | 61 | 22-07-10 |
Members of the board | Title | Age | Since |
---|---|---|---|
Harlan Waksal
CHM | Chairman | 71 | 22-02-15 |
W. Smith
BRD | Director/Board Member | 68 | 19-11-18 |
James Tobin
BRD | Director/Board Member | 79 | 22-03-06 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 0.328 | -1.09% | 958,242 |
24-05-30 | 0.3316 | +0.18% | 1,303,949 |
24-05-29 | 0.331 | -0.75% | 1,287,726 |
24-05-28 | 0.3335 | +2.46% | 1,635,820 |
24-05-24 | 0.3255 | -0.18% | 2,900,474 |
Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-93.74% | 20M | |
+43.36% | 54.64B | |
-5.31% | 39.92B | |
+37.52% | 38.82B | |
+14.75% | 26.86B | |
-12.56% | 26.22B | |
-22.45% | 18.78B | |
+0.04% | 12.16B | |
+25.12% | 12.21B | |
+26.04% | 11.94B |
- Stock Market
- Equities
- LYRA Stock